608141-41-9 | N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$23.00	$16.00
2mg	95%	in stock	$29.00	$20.00
5mg	95%	in stock	$35.00	$24.00
1g	95%	in stock	$41.00	$29.00
5g	95%	in stock	$88.00	$62.00
25g	95%	in stock	$352.00	$246.00
100g	95%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AB52309
• Chemical Name: N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
• CAS Number: 608141-41-9
• Molecular Formula: C22H24N2O7S
• Molecular Weight: 460.5002
• MDL Number: MFCD18782607
• SMILES: CCOc1cc(ccc1OC)[C@H](N1C(=O)c2c(C1=O)c(ccc2)NC(=O)C)CS(=O)(=O)C

Computed Properties

• Complexity: 825
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 8
• XLogP3: 1.8

Literature

• Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

  Expert opinion on pharmacotherapy 20150501

• Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

  Cellular signalling 20140901

• A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.

  Dermatology online journal 20140516

• Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.

  Journal of the American Academy of Dermatology 20130601

• Phosphodiesterase 4-targeted treatments for autoimmune diseases.

  BMC medicine 20130101

• Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

  Lancet (London, England) 20120825

• Apremilast: a step forward in the treatment of psoriasis?

  Lancet (London, England) 20120825

• Novel systemic drugs under investigation for the treatment of psoriasis.

  Journal of the American Academy of Dermatology 20120701

• Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

  Biochemical pharmacology 20120615

• A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.

  Journal of drugs in dermatology : JDD 20120301

• [New therapeutic targets in psoriatic arthritis].

  Reumatologia clinica 20120301

• Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.

  Archives of dermatology 20120201

• Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.

  Xenobiotica; the fate of foreign compounds in biological systems 20111201

• Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

  British journal of pharmacology 20100201

• Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

  Arthritis research & therapy 20100101

• Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

  Journal of medicinal chemistry 20090326

• An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

  Current medical research and opinion 20080501

• 10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.

  Expert opinion on investigational drugs 20060601

• CC-1088 Celgene.

  Current opinion in investigational drugs (London, England : 2000) 20050501

• CC-10004 .

  Current opinion in investigational drugs (London, England : 2000) 20050501

• The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.

  British journal of haematology 20040201